Last reviewed · How we verify
Bismuth containing quadruple therapy — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Bismuth containing quadruple therapy (Bismuth containing quadruple therapy) — Peking University First Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Bismuth containing quadruple therapy TARGET | Bismuth containing quadruple therapy | Peking University First Hospital | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Bismuth containing quadruple therapy CI watch — RSS
- Bismuth containing quadruple therapy CI watch — Atom
- Bismuth containing quadruple therapy CI watch — JSON
- Bismuth containing quadruple therapy alone — RSS
Cite this brief
Drug Landscape (2026). Bismuth containing quadruple therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/bismuth-containing-quadruple-therapy. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab